ClinicalTrials.gg
CompletedNCT02736175Updated Nov 13, 2017Results posted

OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

A Phase 3 interventional study of Dexamethasone and Placebo Vehicle in Post-Surgical Ocular Pain and Post-Surgical Ocular Inflammation, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2015, registered Feb 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing dexamethasone in Pain — 9 open to participants now, 10 under way, 2 of them phase 3. Dexamethasone · Pain.

Enrollment
Largest of 64
438 · median 89
Started
2015
with 2 others
Phase 3
9 of 64
2 open now
Registered
32nd of 64
by date
Lead sponsor
3 of 64
Ocular Therapeutix, Inc.

Among the 64 studies testing dexamethasone in Pain, this one has the largest enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 32nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

9 of the 64 studies testing dexamethasone in Pain are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing dexamethasone in Pain, or all of them as a file.
02

Study summary

The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who had undergone cataract extraction with intraocular lens implantation

03

Conditions studied

  • Post-Surgical Ocular Pain
  • Post-Surgical Ocular Inflammation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of posterior chamber lens
  • Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
  • Score greater than "0" on the Ocular Pain Assessment in the study eye at Screening
  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
438 participants (actual)

Study arms

  • Experimental
    OTX-DP

    OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use

    Drug: Dexamethasone

  • Placebo comparator
    PV

    PV (placebo drug delivery vehicle)

    Other: Placebo Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Absence of Anterior Chamber Inflammation

    Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14

    Time frame: Day 14

  2. Absence of Ocular Pain

    Absence of pain (i.e., score of '0') in the study eye at Day 8

    Time frame: Day 8

07

Results

Posted Oct 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneOTX-DPPlacebo Vehicle
Started216222
Completed214221
Not completed21

Outcome measures

PrimaryAbsence of Anterior Chamber Inflammation

Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14

Time frame:
Day 14
Reported as:
Number · percentage of total participants
Absence of Anterior Chamber Inflammation
percentage of total participantsOTX-DPPlacebo Vehicle
Absence of Anterior Chamber Inflammation52.331.1
PrimaryAbsence of Ocular Pain

Absence of pain (i.e., score of '0') in the study eye at Day 8

Time frame:
Day 8
Reported as:
Number · percentage of total participants
Absence of Ocular Pain
percentage of total participantsOTX-DPPlacebo Vehicle
Absence of Ocular Pain79.661.3

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-DP0/216 (0%)3/216 (1.4%)63/216 (29.2%)
Placebo Vehicle0/221 (0%)2/221 (0.9%)86/221 (38.9%)
Most frequent serious events
Most frequent serious events
EventOTX-DPPlacebo Vehicle
Retinal detachmentEye disorders1/2160/221
Cardiac failure acuteCardiac disorders1/2160/221
Lower gastrointestinal hemorrhageGastrointestinal disorders1/2160/221
NephrolithiasisRenal and urinary disorders0/2161/221
HypoxiaRespiratory, thoracic and mediastinal disorders0/2161/221
Most frequent other events
Most frequent other events
EventOTX-DPPlacebo Vehicle
Adverse EventsGeneral disorders63/21686/221

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)OTX-DPPlacebo VehicleTotal
Mean67.3 ± 9.0968.6 ± 8.3768.0 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)OTX-DPPlacebo VehicleTotal
Female120130250
Male9692188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
Hispanic or Latino373774
Not Hispanic or Latino179185364
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
American Indian or Alaska Native224
Asian819
Native Hawaiian or Other Pacific Islander112
Black or African American282553
White174189363
More than one raceNANANA
Unknown or Not Reported347
Iris Color
Iris Color(Participants)OTX-DPPlacebo VehicleTotal
Brown106101207
Blue6164125
Hazel323769
Green151833
Gray202
Black022
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in May 2016, 7 months.

Results were first posted in Oct 2017, 1 year 5 months after primary completion.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2016
First posted
Apr 13, 2016
StartActual
Oct 2015
Primary completionActual
May 2016
CompletionActual
Jul 2016
Results first posted
Oct 11, 2017
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02736175
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Oct 2015
Primary completion
May 2016
Completion
Jul 2016
Results posted
Oct 11, 2017
Last update
Nov 13, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion